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Background:  Despite  the  large  volume  of studies  on  the  prevention,  diagnosis,  and  treatment  of  peri-
prosthetic  infections,  surgical  practice  often  rests  on  limited  scientiﬁc  evidence  in this ﬁeld.  The  vast
International  Consensus  Meeting  on  Peri-prosthetic  Joint  Infection  (ICMPJI)  held  in  2013  produced  robust
recommendations.
Hypothesis:  French  consensus  conference  recommendations  show  no  major  differences  with  ICMPJI
recommendations.
Materials  and  methods:  The  207  recommendations  developed  by 300  experts  at  the  ICMPJI  were  trans-
lated,  and  the  translation  was  then  examined  by  four  reviewers,  including  2  having  participated  in  the
consensus  conference.  The  reviewers  looked  for any  differences  with  French  practices  and  recommen-
dations.
Results:  Twenty-three  major  differences  or innovations  were  identiﬁed  compared  to  French  recommen-
dations  and  standard  practice.  Among  them,  pre-operative  screening  for nasal  or urinary  micro-organisms
is  performed  routinely  in  France  but  should  be reserved  according  to the  ICMPJI for  symptomatic  patients
and/or patients  at  high  risk  for infection.  The  ICMPJI emphasizes  the  role  for the  operating  room  environ-
ment  as  a  vector  for  infection;  more  speciﬁcally,  the  operating  lamp  handle  and suction  cannula  deserve
close  attention.  A  wound  discharge  persisting  longer  than  5–7  days  requires  irrigation  and  debride-
ment.  This  procedure  is  effective  only  within  the  ﬁrst  3 post-operative  months  and/or  the  ﬁrst  3  weeks
after symptom  onset  and  must  include  exchange  of  all modular  implants.  The  ICMPJI  warns  against  both
irrigation-debridement  in  fungal  infections  (suggesting  two-stage  prosthesis  replacement)  and  one-stage
replacement  in patients  with  sinus  tracts.  The  use  of spacers  (articulating  at the knee)  is  recommended
in  the event  of two-stage  prosthesis  replacement.
Discussion:  The  ICMPJI  recommendations  differed  in  many  ways  with  French  recommendations  and
standard  practice.  They  can  be  expected  to impact  practices  in  France,  although  a point  worth  noting
is  that  only  1  of  the  207 recommendations  received  unanimous  agreement  by  the  conference  experts
(keeping  operating  room  trafﬁ
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. Introduction
Several sources have developed recommendations about the
iagnosis, prevention, and treatment of orthopaedic hardware
nfections [1–5]. Recommendations on prophylactic antibiotic
herapy issued by the French Society for Anaesthesiology and Inten-
ive Care (Société Franc¸ aise d’Anesthésie Réanimation, SFAR) are
pdated regularly (last update, 2010) [1], and the French Soci-
ty for Orthopaedic and Trauma Surgery (Société Franc¸ aise de
hirurgie Orthopédique et de Traumatologie, SOFCOT) has devel-
ped rules for using antibiotic-impregnated cement [2]. In 2009,
hese two societies and the French-Speaking Society for Infectious
iseases (Société de Pathologie Infectieuse de Langue Franc¸ aise,
PILF) held a vast consensus conference about the prevention
nd treatment of orthopaedic hardware infections [3]. In 2013,
wo consensus conferences organized by US organizations (Infec-
ious Diseases Society of America, IDSA [4] and International
onsensus Meeting on Peri-prosthetic Joint Infection [ICMPJI] [5])
ssued recommendations on peri-prosthetic joint infections (PJIs)
hat largely support previous recommendations but also intro-
uce differences regarding many points. Thus, the ICMPJI [5]
dvises against one-stage surgery in the event of a sinus tract,
hereas several French groups found no evidence that a sinus tract
ncreased the risk of one-stage exchange failure [6,7]. Similarly,
he ICMPJI [5] indicates that screening for methicillin-resistant
taphylococcus aureus (MRSA) decreases the risk ofPJI, a conclu-
ion not supported by a meta-analysis by Lévy et al. [8]. Although
xperts from France and other European countries participated
n the ICMPJI, which was directed by Parvizi and Gehrke [5], the
CMPJI recommendations show many differences with standard
ractice and recommendations in Europe. Here, we identify and
iscuss the main differences. Hypothesis: french consensus con-
erence recommendations show no major differences with ICMPJI
ecommendations.
. Materiel and methods
The ICMPJI was held in July 2013 and attended by 300 partici-
ants from 51 countries. The goal of the conference was to obtain
xpert opinions about 15 broad groups of questions in the ﬁeld of
JIs. For each question, the percentages of experts who agreed, dis-
greed, or abstained from voting was used to establish the strength
f the consensus based on the following scale:
simple majority, no consensus (50.1%–59% agreement);
majority, weak consensus (60%–65% agreement);
super majority, strong consensus (66%–99% agreement);
unanimous (100% agreement).
The experts developed 207 recommendations, which were
ranslated into French by a single translator. The translation was
hen corrected and amended by four reviewers (ES, HM,  JNA, and
O), of whom two had participated in the conference (JNA and ES).
hese four reviewers then read the ﬁnal French version and iden-
iﬁed the 25 recommendations deemed most innovative or most
ifferent from French recommendations [3,4]. For editorial rea-
ons, we have conﬁned the present discussion to the 23 variations
hat met  with strong agreement (66%–99%) during the conference.
f these 23 variations, 3 were identiﬁed by all four reviewers, 13
y three reviewers, and 6 by 2 reviewers, as constituting either
nnovations or differences compared to French recommendations.
hese 23 recommendations are described in detail in the results
ection. Surgery & Research 100 (2014) 583–587
3. Results
3.1. Variation 1 (workgroup 1 question 3A): what should the
process be for methicillin-resistant S. aureus (MRSA) and
methicillin-sensitive S. aureus (MSSA) screening?
Consensus: the workgroup does not recommend routine
screening and decolonization of all patients undergoing elective
total arthroplasty (ETA). It accepts that pre-operative screening for
MSSA and MRSA and decolonisation decreases the rate of surgical
site infection (SSI) and the incidence of both staphylococcal and
non-staphylococcal infections.
3.2. Variation 2 (workgroup 1, question 5): what is the role of
routine urine screening in patients undergoing elective
arthroplasty?
Consensus: routine urine screening is not recommended before
ETA. Urine screening before ETA should be reserved for patients
with a present history or symptoms of urinary tract infection.
3.3. Variation 3 (workgroup 3, question 1): what is the optimal
timing of the pre-operative dose of antibiotics?
Consensus: the pre-operative dose of antibiotics should be
administered within 1 hour before the surgical incision; this can be
extended to 2 hours for vancomycin and ﬂuoroquinolones. Surveil-
lance measures are critical in ensuring clinician compliance with
this crucial recommendation.
3.4. Variation 4 (workgroup 3, question 5B): what antibiotic
should be administered in a patient with a known
non-anaphylactic penicillin allergy?
Consensus: in a patient with a reported non-anaphylactic reac-
tion to penicillin, a second-generation cephalosporin can be used
safely, as there is limited cross-reactivity. Penicillin skin testing
may be helpful in certain situations to clarify whether the patient
has a true penicillin allergy.
3.5. Variation 5 (workgroup 3, question 6): what are the
indications for prophylactic vancomycin administration?
Consensus: Vancomycin should be considered in patients who
are current MRSA carriers or who have a known history of anaphy-
lactic allergy to penicillin.
Consideration should be given to screening high risk patients
such as:
• patients in regions with a high prevalence of MRSA;
• institutionalised patients (nursing home residents, chronic
haemodialysis patients, and patients with a history of intensive
care unit admission);
• healthcare workers.
3.6. Variation 6 (workgroup 3, question 17B): should MRSA
carriers or patients with a prior history of MRSA infection be
re-screened? What peri-operative prophylactic antibiotics should
be chosen in these patients?
Consensus: MRSA carriers and patients with a prior history of
MRSA infection should be re-screened pre-operatively. If the tests
are negative for MRSA, routine peri-operative antibiotic prophy-
laxis should be given.
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.7. Variation 7 (workgroup 4, question 6): should operating
ights be controlled with a foot pedal as opposed to a device
ocated above eye level?
Consensus: we recommend a general awareness that light han-
les can be a source of contamination and to minimize handling of
ights as much as possible. Other strategies for light control need
o be developed in the future.
.8. Variation 8 (workgroup 4, question 24): should suction tips
e regularly changed during surgery? If so, how frequently?
hould suction tips enter the femoral canal?
Consensus: we recommend changing suction tips every
0 minutes based on studies showing higher rates of contamina-
ion. Suction tips can be introduced into the femoral canal for the
ime necessary to evacuate ﬂuid but should not be left in the canal,
here they circulate large amounts of ambient air carrying particles
hat may  contaminate the surgery.
.9. Variation 9 (workgroup 7, question 1A): what is the
eﬁnition of peri-prosthetic joint infection (PJI)?
Consensus: PJI is deﬁned as:
two positive peri-prosthetic cultures with pathogens exhibiting
identical antibiotic susceptibility/resistance phenotypes, or;
a sinus tract communicating with the joint, or;
presence of three of the following minor criteria:
◦ elevated serum C-reactive protein (CRP) AND erythrocyte sed-
imentation rate (ESR),
◦ elevated synovial ﬂuid white blood cell (WBC) count OR++ pos-
itive result of urine leukocyte esterase dipstick testing of joint
ﬂuid,
◦ elevated synovial ﬂuid polymorphonuclear neutrophil percent-
age (PMN%),
◦ positive histological analysis of peri-prosthetic tissue,
◦ a single positive culture.
.10. Variation 10 (workgroup 7, question 8): is there a role for
outine sonication of the prosthesis? If so, in which group of
atients should this be done?
Consensus: no. We  do not recommend routine sonication of
mplants. Sonication should be limited to cases of suspected
JI (based on the clinical presentation and screening tests) in
hich pre-operative aspiration does not yield a positive cul-
ure and antibiotics have been administered within the previous
 weeks.
.11. Variation 11 (workgroup 8 question 3B): what are surgical
trategies to address a draining wound after TJA? What are
urgical strategies to address a draining wound after total
rthroplasty?
Consensus: surgical management consisting of opening the fas-
ia, performing a thorough irrigation and debridement (I & D)
ith exchange of modular components should be considered if
ound drainage has persisted for 5 to 7 days after the index
rocedure. Deep specimens for microbiological studies should
e obtained upon re-operation. Wound swab cultures are not
ecommended. Surgery & Research 100 (2014) 583–587 585
3.12. Variation 12 (workgroup 9, question 1): is there a
functional difference in the use of non-articulating or articulating
spacers for the treatment of peri-prosthetic joint infection (PJI) in
the knee, between the two-stages of exchange arthroplasty?
Consensus: articulating spacers provide better function than
non-articulating spacers. An articulating spacer is especially pre-
ferred for patients who  are likely to have a spacer in place for longer
than 3 months.
3.13. Variation 13 (workgroup 9, question 5): is there a difference
in re-implantation (surgical ease) with the use of non-articulating
or articulating spacers for the treatment of PJI in the knee and hip?
Consensus: yes. Re-implantation surgery is easier overall
in patients receiving articulating spacers compared to non-
articulating spacers.
3.14. Variation 14 (workgroup 10, question 1A): when can
irrigation and debridement (I&D) be considered?
Consensus: I & D may  be performed for early post-operative
infections that occur within 3 months of index primary arthroplasty
and within 3 weeks after symptom onset.
3.15. Variation 15 (workgroup 10, question 5): should the
modular part always be exchanged during I&D?
Consensus: yes. All modular components should be removed
and exchanged, if possible.
3.16. Variation 16 (workgroup 10, question 10): should culture
samples be taken during I&D? If so how many and from where?
Consensus: between 3 and 6 tissue and ﬂuid samples should
be taken from the peri-prosthetic region or the most suspicious
regions.
3.17. Variation 17 (workgroup 11, question 1): for antibiotic
therapy, can the oral route be substituted for the intravenous
route for the initial treatment of PJI after resection and while
awaiting exchange prosthesis implantation?
Consensus: there is evidence to support pathogen-speciﬁc,
highly bio-available oral antibiotic therapy for the treatment of PJI
after resection and while awaiting exchange prosthesis implanta-
tion.
3.18. Variation 18 (workgroup 11, question 3): what is the ideal
length of antibiotic treatment following removal of the infected
implant?
Consensus: there is no conclusive evidence regarding the ideal
duration of antibiotic therapy. However, we recommend a period
of antibiotic therapy between 2 to 6 weeks.
3.19. Variation 19 (workgroup 11, question 6): does the use of
rifampin in conjunction with IV antibiotic therapy following
removal of the infected implant lead to a more rapid and
deﬁnitive eradication of staphylococcal infection (particularly
methicillin-resistant S. aureus [MRSA])?Consensus: there is no evidence to support the use of rifampin
in conjunction with IV antibiotic therapy as a more adequate
treatment option than either agent used alone following implant
removal.
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.20. Variation 20 (workgroup 11, question 8): how long should
ntibiotic treatment be given following a single-stage exchange
rthroplasty performed for PJI?
Consensus: there is no conclusive evidence regarding the ideal
uration of antibiotic therapy for a single-stage exchange arthro-
lasty. We  recommend parenteral antibiotic therapy for 2 to 6
eeks after single-stage exchange arthroplasty, with consideration
or longer-term oral antibiotic therapy.
.21. Variation 21 (workgroup 12, question 1): what are the
ndications and contra-indications for one-stage exchange
rthroplasty?
Consensus: one-stage exchange arthroplasty is a reasonable
ption for the treatment of peri-prosthetic joint infection (PJI) in
ircumstances where effective antibiotics are available (rifampin
or Gram-positive cocci and ﬂuoroquinolones for Gram-negative
ods), except in patients with systemic manifestations of infection
sepsis) in whom resection arthroplasty and reduction of bioburden
ay  be necessary. Relative contraindications to performing a one-
tage exchange may  include lack of identiﬁcation of an organism
re-operatively, the presence of a sinus tract or severe soft tissue
nvolvement that may  lead to the need for ﬂap coverage.
.22. Variation 22 (workgroup 13, question 5): what is the best
ay to surgically manage fungal PJI: irrigation and debridement,
ne-stage exchange, two-stage exchange, or permanent resection
rthroplasty?
Consensus: on the basis of the current literature, two-stage
xchange arthroplasty is the recommended treatment option to
anage fungal PJI. However, the success rate is lower than that of
acterial cases.
.23. Variation 23 (workgroup 15, question 4): should
rophylactic antibiotic therapy be given before dental procedures
n patients with total arthroplasties?
Consensus: the decision to use dental antibiotic prophylaxis
n patients with total arthroplasties should rest on the individual
atient-related risk factors and the complexity of the dental proce-
ure to be performed. Patients with total arthroplasty who  are at
igh risk for infection should receive lifetime dental antibiotic pro-
hylaxis. We  recommend the administration of a single antibiotic
ose prior to dental procedures.
. Discussion
The usefulness of S. aureus screening and of decolonisation
easures in the event of a positive result has been established in
eart surgery but not in orthopaedic surgery (Variation 1 [work-
roup 1, question 3-A]. Variation 6 (workgroup 3, question 17B)
ecommends re-screening of known MRSA carriers followed by
tandard prophylactic antibiotic therapy in the event of a nega-
ive result. For the pre-operative work-up, Variation 2 (workgroup
, question 5) does not recommend screening for asymptomatic
acteriuria before arthroplasty and reserves urine microscopy and
ulture for patients with symptoms.
The interval recommended by the ICMPJI between prophylac-
ic antibiotic administration and the incision is 1 hour (Variation
 [workgroup 3, question 1]) compared to only 30 minutes
n previous recommendations [1]. Use of a second-generation
ephalosporin (C2G) is suggested for patients with penicillin
llergy. The risk of cross-reactions between penicillin and C3G is
sually recognised as very small, less than 5%, and although this risk Surgery & Research 100 (2014) 583–587
seems higher with C2G the ICMPJI recommendations suggest the
use of these drugs in patients with severe allergic manifestations
and after allergen testing if appropriate (Variation 4 [workgroup
3, question 5B]). This recommendation constitutes a major depar-
ture from the strategy advised by the SFAR, which involves using a
glycopeptide or clindamycinin patients with beta-lactam allergies
[1]. Prophylactic vancomycin therapy should be reserved, accord-
ing to the ICMPJI recommendation, for conﬁrmed MRSA carriers
(variation 5 [workgroup 3 question 6]), whereas the SFAR advises
that vancomycin be given to all patients potentially colonised by
nosocomial organisms [1]. In addition, the ICMPJI (Variation 6
[workgroup 3 question 17B]) recommends re-screening of patients
with a history of carriage followed by the use of glycopeptides only
in the event of a positive result. French recommendations [1–3] do
not mention the risks related to operating light handles or suction
cannulas (Variation 7 [workgroup 4, question 6] and Variation 8
[workgroup 4, question 24]).
The ICMPJI deﬁnition of prosthetic joint infection (Variation 9
[workgroup, 7 question 1A]) rests on the presence in two  reliable
samples (joint aspiration or intra-operative samples) containing
the same micro-organism (that is, exhibiting identical antibiotic
susceptibilities). This deﬁnition differs noticeably from that sug-
gested in the IDSA consensus [4] (in which one or two  cultures
positive for a bacterial skin saprophyte are not sufﬁcient to estab-
lish a diagnosis of PJI) and in the SPLIF consensus [2] (which requires
a sample positive for a non-saprophyte or three cultures positive
for a saprophyte). The group of ICMPJI experts reserved implant
sonication to situations in which pre-operative documentation of
the infection is in doubt and/or antibiotic therapy was given within
2 weeks before surgery, as this treatment might presumably result
in negative intra-operative cultures (Variation 10 [workgroup 7,
question 8]). Implant sonication is not performed routinely in most
centres and its modalities are not fully standardised. In addition,
implant sonication has not been proven to modify patient out-
comes.
The management of wound drainage for longer than 5 days
requires opening the incision (Variation 11 [workgroup 8, ques-
tion 3B]). A crucial point is that no antibiotics should be started
before this procedure. Emphasis should be put on the unfortu-
nately widespread practice of obtaining samples from the incision
and using the results to determine the need for antibiotic therapy.
Inappropriate antibiotic therapy is unlikely to be effective in the
absence of irrigation-debridement surgery and diminishes the like-
lihood of documenting the surgical site infection and therefore of
selecting the optimal antibiotics. The French consensus conferences
[2,3] did not underline the role for spacers in two-stage exchange
arthroplasty and the importance of using articulating spacers at
the knee (Variation 12 [workgroup 9, question 1] and Variation 13
[workgroup 9, question 5]), due both to a paucity of data and to a
growing preference in France for one-stage exchange [6,7]. During
re-operation for irrigation-debridement, the ICMPJI recommenda-
tions include taking several samples for microbiological cultures
(Variation 16 [workgroup 10, question 10]) and changing modu-
lar implant components (Variation 15 [workgroup 10 question 5]),
which constitute an adherence surface for the bioﬁlm and therefore
a major source of antibiotic treatment failure. The maximum times
of 3 months after implantation and 3 weeks after symptom onset
for performing irrigation-debridement (Variation 14 [workgroup
10, question 1A]) are somewhat longer than those suggested by the
IDSA and by French recommendations (4 weeks after implantation
and 3 weeks of clinical evidence of active infection) [3,4].
The antibiotics believed to be effective in PJI (rifampin for
Gram-positive cocci and ﬂuoroquinolones for Gram-negative rods)
(Variation 17 [workgroup 11, question 1]) are those characterised
by the best oral bioavailability (> 90% for rifampin and levoﬂoxacin).
Consequently, a rapid switch to the oral route seems reasonable
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hen these antibiotics are started parenterally (Variation 19 [work-
roup 11, question 6]). Oral treatment from the outset has not been
alidated in PIJ and may  be limited by the gastric tolerance prob-
ems that are common immediately after surgery. After one-stage
xchange, parenteral antibiotic therapy is recommended for 4-6
eeks (Variation 20 [workgroup 11, question 8]), compared to 1
eek in French recommendations [2,6].
The ICMPJI recommendations given preference to one-stage
xchange arthroplasty except in patients with sepsis with systemic
anifestations, sinus tracts, fungal infections, or extensive soft
issue lesions that may  require ﬂap coverage (Variation 21 [work-
roup 12, question 1] and Variation 22 [workgroup 13, question
]).
In the event of two-stage exchange arthroplasty, the ICMPJI
xperts recommend 4–6 weeks as the optimal antibiotic therapy
uration after implant removal (Variation 18 [workgroup 11, ques-
ion 3]). The SPILF, in contrast, suggests two options, either a brief
nterval of 4–6 weeks or a long interval of 3–6 months [2].
Finally, the ICMPJI adopted the recommendations issued by the
arious professional societies (NICE, American and French Den-
al Societies, and European Society of Cardiology) regarding the
bsence of beneﬁts from prophylactic antibiotic therapy during
ental procedures, except those known to carry a high risk of bac-
eraemia (Variation 23 [workgroup 15, question 4]) [9].
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